Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation

Liver Transplantation

Volumn 15, Issue 1, 2009, Pages 15-19

  Hemnes, Anna R ^a   Robbins, Ivan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL;

ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FUNCTION TEST; HEART CATHETERIZATION; HEART INDEX; HEPATITIS C; HUMAN; HYPOTENSION; LIVER FUNCTION; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MONOTHERAPY; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; WALKING SPEED;

FEMALE; FIBROSIS; HEMODYNAMICS; HEPACIVIRUS; HEPATITIS C; HUMANS; HYPERTENSION, PULMONARY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PIPERAZINES; PURINES; RETROSPECTIVE STUDIES; SULFONES; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 64049112788     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21479     Document Type: Article

References (22)

1. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996;71:543-551.
2. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003;52:1355-1362.
3. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443-450.
4. Starkel P, Vera A, Gunson B, Mutimer D. Outcome of liver transplantation for patients with pulmonary hypertension. Liver Transpl 2002;8:382-388.
5. Schott R, Chaouat A, Launoy A, Pottecher T, Weitzenblum E. Improvement of pulmonary hypertension after liver transplantation. Chest 1999;115:1748-1749.
6. Csete M. Intraoperative management of liver transplant patients with pulmonary hypertension. Liver Transpl Surg 1997;3:454-455.
7. Scott V, De Wolf A, Kang Y, Martin M, Selby R, Fung J, et al. Reversibility of pulmonary hypertension after liver transplantation: a case report. Transplant Proc 1993;25: 1789-1790.
8. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007;7:1258-1264.
9. Hinderliter AL, Willis PWT, Barst RJ, Rich S, Rubin LJ, Badesch DB, et al., for the Primary Pulmonary Hypertension Study Group. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-1486.
10. Pavlovic M, Petkovic D, Cvetkovic M, Zdjelar K, Starcevic V, Bosnic O. Study of the mechanism of prostacyclin (PgI2) action on myocardial contractility. Agents Actions Suppl 1992;37:171-175.
11. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.
12. Callejas Rubio JL, Salmeron Escobar J, Gonzalez-Calvin J, Ortego Centeno N. Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil. Liver Transpl 2006;12:690-691.
13. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006;28:563-567.
14. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004;10:945-950.
15. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436-2441.
16. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
17. Deibert P, Bremer H, Roessle M, Kurz-Schmieg AK, Kreisel W. PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension. Eur Respir J 2007;29: 220-221.
18. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030.
19. Grander W, Eller P, Fuschelberger R, Tilg H. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest 2006; 36(suppl 3):67-70.
20. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-508.
21. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-648.
22. Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 2005;334:930-938.